
CRIS
Curis
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 3
stock price surged significantly
consensus rating "Strong Buy"
EPS Below Expectations
Revenue Below Expectations
Revenue Keeps Dropping
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CRIS
Curis, Inc.
A biotechnology company that developing innovative therapeutics for the treatment of cancer
128 Spring Street, Building C - Suite 500, Lexington, Massachusetts, 02421
--
Curis, Inc., was incorporated as a Delaware corporation in February 2000. The company is a biotechnology company focused on the development of emavusertib, an oral, small-molecule inhibitor of the interleukin -1 receptor-associated kinase.
Company Financials
EPS
CRIS has released its 2024 Q4 earnings. EPS was reported at -1.25, versus the expected -1.24, missing expectations. The chart below visualizes how CRIS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CRIS has released its 2024 Q4 earnings report, with revenue of 3.35M, reflecting a YoY change of 24.07%, and net profit of -9.62M, showing a YoY change of 17.88%. The Sankey diagram below clearly presents CRIS’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available